Nine patients aged 15 to 37 years with Gilles de la Tourette syndrome
inadequately controlled by conventional agents were given open-label t
reatment with carbamazepine. Symptoms rapidly worsened in the first th
ree patients who were given 600 to 800 mg/d. Lower dosages (100 to 400
mg/d) were used in subsequent patients. Responses varied across patie
nts. No conclusions on the efficacy of carbamazepine in this indicatio
n can be drawn based on this study.